Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant

Lisa M. Butler, Margaret M. Centenera, Petra J. Neufing, Grant Buchanan, Catherine S Y Choong, Carmela Ricciardelli, Kathleen Saint, Melissa Lee, Aleksandra Ochnik, Miao Yang, Michael P. Brown, Wayne D. Tilley

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

There is increasing evidence that sensitization of the androgen receptor (AR) signaling pathway contributes to the failure of androgen ablation therapy for prostate cancer, and that direct targeting of the AR may be a useful therapeutic approach. To better understand how AR function could be abrogated in prostate cancer cells, we have developed a series of putative dominant-negative variants of the human AR, containing deletions or mutations in activation functions AF-1, AF-5, and/or AF-2. One construct, AR inhibitor (ARi)-410, containing a deletion of AF-1 and part of AF-5 of the AR, had no intrinsic transactivation activity but inhibited wildtype AR (wtAR) in a ligand-dependent manner by at least 95% when transfected at a 4:1 molar ratio. ARi-410 was an equally potent inhibitor of gain-offunction AR variants. Ectopic expression of ARi-410 inhibited the proliferation of AR-positive LNCaP cells, but not AR-negative PC-3 cells. Whereas ARi-410 also marginally inhibited progesterone receptor activity, this was far less pronounced than the effect on AR (50% vs. 95% maximal inhibition, respectively), and there was no inhibition of either vitamin D or estrogen receptor activity. In the presence of ligand, ARi-410 interacted with wtAR, and both receptors translocated into the nucleus. Whereas the amino-carboxy terminal interaction was not necessary for optimal dominant-negative activity, disruption of dimerization through the ligand binding domain reduced the efficacy of ARi-410. In addition, although inhibition of AR function by ARi-410 was not dependent on DNA binding, the DNA binding domain was required for dominant-negative activity. Taken together, our results suggest that interaction between ARi-410 and the endogenous AR in prostate cancer cells, potentially through the DNA binding and ligand binding domains, results in a functionally significant reduction in AR signaling and AR-dependent cell growth.

LanguageEnglish
Pages1009-1024
Number of pages16
JournalMolecular Endocrinology
Volume20
Issue number5
DOIs
Publication statusPublished - 1 May 2006

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology

Cite this

Butler, L. M., Centenera, M. M., Neufing, P. J., Buchanan, G., Choong, C. S. Y., Ricciardelli, C., ... Tilley, W. D. (2006). Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. Molecular Endocrinology, 20(5), 1009-1024. https://doi.org/10.1210/me.2004-0401
Butler, Lisa M. ; Centenera, Margaret M. ; Neufing, Petra J. ; Buchanan, Grant ; Choong, Catherine S Y ; Ricciardelli, Carmela ; Saint, Kathleen ; Lee, Melissa ; Ochnik, Aleksandra ; Yang, Miao ; Brown, Michael P. ; Tilley, Wayne D. / Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. In: Molecular Endocrinology. 2006 ; Vol. 20, No. 5. pp. 1009-1024.
@article{e5ff0476281e4a2481f799820183fb57,
title = "Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant",
abstract = "There is increasing evidence that sensitization of the androgen receptor (AR) signaling pathway contributes to the failure of androgen ablation therapy for prostate cancer, and that direct targeting of the AR may be a useful therapeutic approach. To better understand how AR function could be abrogated in prostate cancer cells, we have developed a series of putative dominant-negative variants of the human AR, containing deletions or mutations in activation functions AF-1, AF-5, and/or AF-2. One construct, AR inhibitor (ARi)-410, containing a deletion of AF-1 and part of AF-5 of the AR, had no intrinsic transactivation activity but inhibited wildtype AR (wtAR) in a ligand-dependent manner by at least 95{\%} when transfected at a 4:1 molar ratio. ARi-410 was an equally potent inhibitor of gain-offunction AR variants. Ectopic expression of ARi-410 inhibited the proliferation of AR-positive LNCaP cells, but not AR-negative PC-3 cells. Whereas ARi-410 also marginally inhibited progesterone receptor activity, this was far less pronounced than the effect on AR (50{\%} vs. 95{\%} maximal inhibition, respectively), and there was no inhibition of either vitamin D or estrogen receptor activity. In the presence of ligand, ARi-410 interacted with wtAR, and both receptors translocated into the nucleus. Whereas the amino-carboxy terminal interaction was not necessary for optimal dominant-negative activity, disruption of dimerization through the ligand binding domain reduced the efficacy of ARi-410. In addition, although inhibition of AR function by ARi-410 was not dependent on DNA binding, the DNA binding domain was required for dominant-negative activity. Taken together, our results suggest that interaction between ARi-410 and the endogenous AR in prostate cancer cells, potentially through the DNA binding and ligand binding domains, results in a functionally significant reduction in AR signaling and AR-dependent cell growth.",
author = "Butler, {Lisa M.} and Centenera, {Margaret M.} and Neufing, {Petra J.} and Grant Buchanan and Choong, {Catherine S Y} and Carmela Ricciardelli and Kathleen Saint and Melissa Lee and Aleksandra Ochnik and Miao Yang and Brown, {Michael P.} and Tilley, {Wayne D.}",
year = "2006",
month = "5",
day = "1",
doi = "10.1210/me.2004-0401",
language = "English",
volume = "20",
pages = "1009--1024",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "5",

}

Butler, LM, Centenera, MM, Neufing, PJ, Buchanan, G, Choong, CSY, Ricciardelli, C, Saint, K, Lee, M, Ochnik, A, Yang, M, Brown, MP & Tilley, WD 2006, 'Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant', Molecular Endocrinology, vol. 20, no. 5, pp. 1009-1024. https://doi.org/10.1210/me.2004-0401

Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. / Butler, Lisa M.; Centenera, Margaret M.; Neufing, Petra J.; Buchanan, Grant; Choong, Catherine S Y; Ricciardelli, Carmela; Saint, Kathleen; Lee, Melissa; Ochnik, Aleksandra; Yang, Miao; Brown, Michael P.; Tilley, Wayne D.

In: Molecular Endocrinology, Vol. 20, No. 5, 01.05.2006, p. 1009-1024.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant

AU - Butler, Lisa M.

AU - Centenera, Margaret M.

AU - Neufing, Petra J.

AU - Buchanan, Grant

AU - Choong, Catherine S Y

AU - Ricciardelli, Carmela

AU - Saint, Kathleen

AU - Lee, Melissa

AU - Ochnik, Aleksandra

AU - Yang, Miao

AU - Brown, Michael P.

AU - Tilley, Wayne D.

PY - 2006/5/1

Y1 - 2006/5/1

N2 - There is increasing evidence that sensitization of the androgen receptor (AR) signaling pathway contributes to the failure of androgen ablation therapy for prostate cancer, and that direct targeting of the AR may be a useful therapeutic approach. To better understand how AR function could be abrogated in prostate cancer cells, we have developed a series of putative dominant-negative variants of the human AR, containing deletions or mutations in activation functions AF-1, AF-5, and/or AF-2. One construct, AR inhibitor (ARi)-410, containing a deletion of AF-1 and part of AF-5 of the AR, had no intrinsic transactivation activity but inhibited wildtype AR (wtAR) in a ligand-dependent manner by at least 95% when transfected at a 4:1 molar ratio. ARi-410 was an equally potent inhibitor of gain-offunction AR variants. Ectopic expression of ARi-410 inhibited the proliferation of AR-positive LNCaP cells, but not AR-negative PC-3 cells. Whereas ARi-410 also marginally inhibited progesterone receptor activity, this was far less pronounced than the effect on AR (50% vs. 95% maximal inhibition, respectively), and there was no inhibition of either vitamin D or estrogen receptor activity. In the presence of ligand, ARi-410 interacted with wtAR, and both receptors translocated into the nucleus. Whereas the amino-carboxy terminal interaction was not necessary for optimal dominant-negative activity, disruption of dimerization through the ligand binding domain reduced the efficacy of ARi-410. In addition, although inhibition of AR function by ARi-410 was not dependent on DNA binding, the DNA binding domain was required for dominant-negative activity. Taken together, our results suggest that interaction between ARi-410 and the endogenous AR in prostate cancer cells, potentially through the DNA binding and ligand binding domains, results in a functionally significant reduction in AR signaling and AR-dependent cell growth.

AB - There is increasing evidence that sensitization of the androgen receptor (AR) signaling pathway contributes to the failure of androgen ablation therapy for prostate cancer, and that direct targeting of the AR may be a useful therapeutic approach. To better understand how AR function could be abrogated in prostate cancer cells, we have developed a series of putative dominant-negative variants of the human AR, containing deletions or mutations in activation functions AF-1, AF-5, and/or AF-2. One construct, AR inhibitor (ARi)-410, containing a deletion of AF-1 and part of AF-5 of the AR, had no intrinsic transactivation activity but inhibited wildtype AR (wtAR) in a ligand-dependent manner by at least 95% when transfected at a 4:1 molar ratio. ARi-410 was an equally potent inhibitor of gain-offunction AR variants. Ectopic expression of ARi-410 inhibited the proliferation of AR-positive LNCaP cells, but not AR-negative PC-3 cells. Whereas ARi-410 also marginally inhibited progesterone receptor activity, this was far less pronounced than the effect on AR (50% vs. 95% maximal inhibition, respectively), and there was no inhibition of either vitamin D or estrogen receptor activity. In the presence of ligand, ARi-410 interacted with wtAR, and both receptors translocated into the nucleus. Whereas the amino-carboxy terminal interaction was not necessary for optimal dominant-negative activity, disruption of dimerization through the ligand binding domain reduced the efficacy of ARi-410. In addition, although inhibition of AR function by ARi-410 was not dependent on DNA binding, the DNA binding domain was required for dominant-negative activity. Taken together, our results suggest that interaction between ARi-410 and the endogenous AR in prostate cancer cells, potentially through the DNA binding and ligand binding domains, results in a functionally significant reduction in AR signaling and AR-dependent cell growth.

UR - http://www.scopus.com/inward/record.url?scp=33746510806&partnerID=8YFLogxK

U2 - 10.1210/me.2004-0401

DO - 10.1210/me.2004-0401

M3 - Article

VL - 20

SP - 1009

EP - 1024

JO - Molecular Endocrinology

T2 - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 5

ER -